BioBlog

As the world continues to battle the novel coronavirus (COVID-19), drug companies, healthcare providers, and others are facing unprecedented challenges, too. Bristol-Myers-Squibb joins the list of companies halting introductions and clinical trials during the pandemic. Humana and Cigna waive

The novel coronavirus (COVID-19) has impacted every aspect of life. The biggest impact has been on the healthcare system, which finds itself adapting as quickly as possible to the pandemic threat. Lily joins a list of companies halting or stopping clinical trials temporarily until the pandemic is

Innovation Partners’ BioBlog looks at the impact of the COVID-19 epidemic. The coronavirus, COVID-19, has swept the world, prompting unprecedented measures here and abroad to prevent its spread and contain the outbreak. Hospitals press Congress to end or pause Medicare sequester cuts; a new FAQ

This week, we find many medical and healthcare industry conferences announcing cancellations, postponements, and moves to virtual conferences to prevent the spread of COVID-19. The fear is that healthcare industry attendees may inadvertently return to their workplaces bearing COVID-19 and spread the

In this week’s Innovation Partners BioBlog, we look at the top stories from the world of healthcare. Eli Lilly reassured its customers that its drug supply, especially its stock of insulin, remains safe and unaffected by the COVID-19 outbreak. The Supreme Court has agreed to hear a case brought by

In this week’s Innovation Partners BioBlog, we report on health insurers profit with UnitedHealth the most profitable followed by CVS. Oscar Health is taking the extraordinary step of offering 100 medications at $3 each to encourage patients to continue taking much-needed medicines for chronic

The American Society of Clinical Oncology’s Genitourinary Cancers Symposium provides several top stories this week including a promising combination therapy from Bristol-Myers Squibb and an announcement from Mustang Bio. The FDA announced they are halting inspections of Chinese plants due to the

This week’s Innovation Partners BioBlog looks at ideas shaping the future of healthcare. Trump’s new budget includes four items that, although unlikely to pass through Congress, give a glimpse into the president’s priorities. Oncology biosimilars are on the rise with physicians starting new patients